On November 29, 2018 Clinical Genomics, a leading provider of cancer diagnostic solutions including liquid biopsy tests, reported its partnership with the Colorectal Cancer Alliance in a yearlong collaboration for the Life After Cancer mission (Press release, Clinical Genomics, NOV 29, 2018, View Source [SID1234531709]). The Alliance is the largest US-based nonprofit patient advocacy group for colorectal cancer patients, providing resources and education to patients in their fight against this disease. The Life After Cancer initiative focuses on helping patients navigate their survivorship path by creating awareness about recurrence monitoring as part of their follow up care, allowing those who have overcome the disease to become an advocate of their long-term health and well-being. This expanded partnership between Clinical Genomics and the Colorectal Cancer Alliance builds upon an existing relationship to continue the mission to support this patient community.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Clinical Genomics is the sole provider of COLVERA, a unique blood test for patients who have been diagnosed with colorectal cancer (CRC) that identifies circulating tumor DNA (ctDNA) for early detection of residual and recurrent disease, at a stage when more treatment options are available for these patients. COLVERA is currently marketed in the USA and available through our CLIA-certified laboratory in Bridgewater, NJ.
"Early detection has been shown to improve overall survival from this deadly disease. Colorectal cancer affects a wide range of ages with increasing incidence in younger patients. Partnerships like this with Clinical Genomics are critical in order to make an impact on this devasting disease and provide patients with cutting edge tools and resources they need in order to navigate their choices," stated Michael Sapienza, CEO of the Colorectal Cancer Alliance.
"We had the great pleasure to meet patients and their circle of support at the Alliance’s National Conference in Houston this year. Working with the Alliance on Life After Cancer, we can contribute to providing important education and awareness resources to this community. Colorectal cancer screening is an important focus in the US and now we must emphasize the importance of follow-up care surveillance monitoring of CRC with tests like COLVERA, for patients who have been diagnosed with the disease," said Betsy Hanna, Chief Commercial Officer of Clinical Genomics.
About Colorectal Cancer
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer related deaths in the United States, with more than 140,000 people per year expected to be diagnosed with CRC and as many as 50,000 succumbing to the disease. For patients who survive, 30-50% will experience a recurrence, most within the first two to three years of primary treatment. On average, the lifetime risk of developing colorectal cancer is about one in 23 for men and women combined, however, this varies widely according to individual risk factors.